CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast CancerOctober 12, 2016
Adding ribociclib to letrozole significantly improves progression-free survival for postmenopausal women with metastatic hormone receptor (HR)-positive breast cancer, compared with hormone therapy alone.
Adding daratumumab to lenalidomide and dexamethasone significantly prolonged progression-free survival compared with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.
Patients with oropharyngeal tumors that harbor HPV16 have higher 5-year survival and lower recurrence rates than patients with tumors that harbor other HPV strains or are HPV-negative.
Continued adoption of stereotactic body radiation therapy (SBRT) to treat early stage NSCLC improved OS and lung cancer-specific survival, according to a study presented at the 2016 annual meeting of the American Society for Radiation Oncology.
The combination of adjuvant bevacizumab and capecitabine failed to improve disease-free survival compared with capecitabine alone in patients with mCRC who had undergone potentially curative surgery.
Hematopoietic stem cell transplantation (HCT) is found to increase expression of a genetic code used to make proteins, leading to a biological aging of immune cells equivalent to 30 years of chronological age.
[Journal of Gastrointestinal Oncology] This research examines factors associated with survival in patients with brain metastasis from esophageal cancer.
HIV is associated with reduced cancer-specific survival among women with invasive cervical cancer.
Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple MyelomaAugust 16, 2016
The addition of elotuzumab to bortezomib/dexamethasone appears to increase progression-free survival in relapsed/refractory multiple myeloma (RRMM).
Patients with metastatic non-small cell lung cancer demonstrated prolonged median progression-free survival with the administration of erlotinib below the maximum tolerated dose.
Research indicates that metformin can confer improved survival for patients with colorectal cancer that also have diabetes.
Treatment with daratumumab, lenalidomide, and dexamethasone (DRd) may be superior to lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma.
Dasatinib and nilotinib are associated with similar response rates and survival outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).
Use of androgen suppression therapy may negatively impact survival in African American patients with favorable-risk prostate cancer.
Survival among women age 40 years and younger with breast cancer appears to vary according to breast cancer subtype, with age particularly prognostic for women with luminal type breast cancers.
As salvage radiotherapy (SRT) outcomes may be affected by factors associated with prostatectomy findings, they may be positively affected when used at lower prostate-specific antigen (PSA) levels.
A very large retrospective study of patients with stage II colon cancer found adjuvant therapy improves survival, regardless of treatment regimen, patient age, or high-risk pathologic risk features.
Telomere length is predictive for determining which children treated for AML are at highest risk for delayed recovery, a finding that may have significant implications for treatment-related morbidity and mortality.
Memory problems in breast cancer survivors appear associated with the high stress load these patients experience rather than their treatment, and moderate-to-vigorous physical activity may help subjective memory in these patients.
Lung cancers that manifest as nonsolid nodules seem to have indolent course, according to recent research data.
Many Older Women With Early Stage Breast Cancer Are Susceptible to Functional Decline After Starting TreatmentJuly 05, 2016
Approximately 20% of older women with stage I-III breast cancer lost the ability to complete some basic tasks of independent living within 1 year of starting treatment. However, an assessment tool can identify those women at greatest risk of posttreatment functional decline.
Gross total resection to treat glioblastoma multiforme (GBM) showed progression-free survival benefits over subtotal resection and biopsy in a meta-analysis of 37 studies.
Recent results from a multicenter, phase 2 trial suggest that patients with HIV and aggressive lymphoma should receive autologous stem cell transplant as standard of care. Risk of serious complications after transplant in these patients is equal to that of patients without HIV.
Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL.
In a randomized phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with ALL whose disease had relapsed following standard therapies, qualified for stem cell transplants after treatment with the drug.
Event-free survival for adult patients with ALL has improved from 40% to 73% with the implementation of the NOPHO ALL 2008 protocol in July 2008.
Adjuvant chemotherapy in patients with stage Ib non-small cell lung cancer improved overall survival and 5-year overall survival.
The number of patients older than 75 years who do not undergo surgery is increasing, especially among those with stage III or IV ovarian cancer. Approximately 50% do not undergo surgery and 25% receive no treatment at all.
New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent MetastasesJune 16, 2016
Researchers demonstrate how breast cancer cells invade bone marrow, where they escape chemotherapy and hormonal therapies that would otherwise eliminate the cancer cells.
Metastatic capabilities of pancreatic cancer might arise before tumors even form. Metastasis and advanced stage of disease at diagnosis are attributed to low survival rates for pancreatic cancer.
- Beta-blockers May Improve Survival in Multiple Myeloma
- Preventing Tumor Lysis Syndrome in Patients Receiving Venetoclax
- Thalidomide, Lenalidomide Equivalent With Respect to Survival in Myeloma
- LIVESTRONG Exercise Program Improves QoL in Cancer Survivors
- Rasburicase More Effective Than Allopurinol for Tumor Lysis Syndrome
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Alternating Pazopanib and Everolimus Treatment Schedule Not Effective for RCC
- Adding Onartuzumab to Chemo Not Effective for HER2-, MET+ Gastroesophageal Adenocarcinoma
- Rasburicase More Effective Than Allopurinol for Tumor Lysis Syndrome
- Mental Health Disorder Linked to Poorer Survival in NSCLC
- Perindopril, Bisoprolol Not Effective for Preventing Trastuzumab-mediated Left Ventricular Remodeling
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|